SCD-044 for Eczema
(SOLARES-AD-1 Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing a new medication called SCD-044 to see if it can help people with moderate to severe atopic dermatitis by reducing symptoms like itching and inflammation.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
How is the drug SCD-044 for eczema different from other treatments?
SCD-044 is unique because it involves multiple dosage levels being tested, which may help determine the most effective dose for treating eczema. Unlike standard treatments like topical corticosteroids or systemic immunosuppressants, SCD-044's specific mechanism of action and its potential benefits over existing therapies are still being explored in clinical trials.12345
Eligibility Criteria
This trial is for adults over 18 with moderate to severe atopic dermatitis (eczema) that's been diagnosed for at least a year. It's not open to pregnant or nursing women, those planning pregnancy soon, or individuals with complications from diabetes like kidney issues, eye problems, or neuropathy.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive SCD-044 or placebo tablets for the treatment of moderate to severe atopic dermatitis
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Placebo
- SCD-044_Dose 1
- SCD-044_Dose 2
- SCD-044_Dose 3
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sun Pharmaceutical Industries Limited
Lead Sponsor
Dilip Shanghvi
Sun Pharmaceutical Industries Limited
Chief Executive Officer since 1993
Majored in Cellular and Molecular Biology at the University of Michigan – Ann Arbor
Dr. Azadar H. Khan
Sun Pharmaceutical Industries Limited
Chief Medical Officer since 2023
MD from a recognized institution